跳至主要内容
临床试验/NCT02581592
NCT02581592已完成1 期

The Effect of Moderate Hepatic Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD-4208

Mylan Inc.1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2015年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Mylan Inc.
入组人数
16
试验地点
1
主要终点
Maximum observed plasma concentration (Cmax)

研究概览

简要总结

This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of TD-4208.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • For hepatic impairment group: Subject has moderate hepatic impairment (Child Pugh B)
  • For normal hepatic function group: Subject is in good health

排除标准

  • Women who are pregnant, lactating, breastfeeding, or planning to become pregnant during the study.
  • Subject has received an investigational drug (or medical device) within 30 days
  • Subject who, for any reason, is deemed by the investigator to be inappropriate for this study; or has any condition that would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug; or is unable to comply with the study protocol.

研究组 & 干预措施

Hepatic Impairment

Experimental

Eight subjects with Moderate Hepatic Impairment (Child-Pugh B). Drug: TD-4208 175mcg, inhaled, single dose.

干预措施: TD-4208 (Drug)

Normal Hepatic Function

Experimental

Eight healthy participants matched to participants with moderate hepatic impairment. Drug: TD-4208 175mcg, inhaled, single dose.

干预措施: TD-4208 (Drug)

结局指标

主要结局

Maximum observed plasma concentration (Cmax)

时间窗: Predose; 5min, 15min, 30 min; 1hr, 2hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24hr, 36hr, 48hr, 72hr, 96hr post dose

TD-4208 Cmax, derived from plasma concentration-time curves

次要结局

  • Adverse Events (AE)(From the time of study drug administration through the end of the study (Day 5 or early termination))

研究者

发起方
Mylan Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Pharmacokinetics of TD-4208 in Patients With... | 临床试验